At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Enzastaurindrug
Likely dose
Enzastaurin 1125 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Enzastaurin for Cutaneous T-Cell Lymphoma. Completed, enrolled 25 participants across 16 sites.
Detailed Summary
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous T-Cell Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartSep 2008
Primary CompletionJan 2010
Study CompletionFeb 2010
TodayJul 2026
First PostedSep 1, 2008
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2010
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago
Interventions
Enzastaurindrug
1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression